Found: 24
Select item for more details and to access through your institution.
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 6, p. 1239, doi. 10.1111/bjh.18815
- By:
- Publication type:
- Article
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
- Published in:
- British Journal of Haematology, 2020, v. 191, n. 1, p. 52, doi. 10.1111/bjh.16857
- By:
- Publication type:
- Article
The poor prognosis of low hypodiploidy in adults with B‐cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 2, p. 263, doi. 10.1111/bjh.15887
- By:
- Publication type:
- Article
Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma.
- Published in:
- Journal of Clinical Apheresis, 2012, v. 27, n. 5, p. 260, doi. 10.1002/jca.21234
- By:
- Publication type:
- Article
Molecular profiling refines minimal residual disease‐based prognostic assessment in adults with Philadelphia chromosome‐negative B‐cell precursor acute lymphoblastic leukemia.
- Published in:
- Genes, Chromosomes & Cancer, 2019, v. 58, n. 11, p. 815, doi. 10.1002/gcc.22788
- By:
- Publication type:
- Article
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 2, p. 451, doi. 10.1007/s00277-023-05582-y
- By:
- Publication type:
- Article
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry.
- Published in:
- Cancers, 2022, v. 14, n. 9, p. N.PAG, doi. 10.3390/cancers14092342
- By:
- Publication type:
- Article
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.
- Published in:
- Cancers, 2022, v. 14, n. 7, p. 1734, doi. 10.3390/cancers14071734
- By:
- Publication type:
- Article
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial.
- Published in:
- Cancers, 2021, v. 13, n. 10, p. 2458, doi. 10.3390/cancers13102458
- By:
- Publication type:
- Article
A pediatric regimen for adolescents and young adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 7, p. 2317, doi. 10.1002/cam4.2814
- By:
- Publication type:
- Article
Increased survival due to lower toxicity for high‐risk T‐cell acute lymphoblastic leukemia patients in two consecutive pediatric‐inspired PETHEMA trials.
- Published in:
- European Journal of Haematology, 2019, v. 102, n. 1, p. 79, doi. 10.1111/ejh.13178
- By:
- Publication type:
- Article
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.
- Published in:
- European Journal of Haematology, 2015, v. 95, n. 6, p. 576, doi. 10.1111/ejh.12538
- By:
- Publication type:
- Article
Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
- Published in:
- European Journal of Haematology, 2014, v. 93, n. 6, p. 487, doi. 10.1111/ejh.12386
- By:
- Publication type:
- Article
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00839-1
- By:
- Publication type:
- Article
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00839-1
- By:
- Publication type:
- Article
A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 4, p. 1, doi. 10.1038/s41408-020-0308-3
- By:
- Publication type:
- Article
Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms.
- Published in:
- Genes, Chromosomes & Cancer, 2017, v. 56, n. 11, p. 810, doi. 10.1002/gcc.22486
- By:
- Publication type:
- Article
Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.1054458
- By:
- Publication type:
- Article
Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML.
- Published in:
- Genes, 2020, v. 11, n. 1, p. 73, doi. 10.3390/genes11010073
- By:
- Publication type:
- Article
A phase 3 trial of azacitidine versus a semi‐intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 12, p. 2003, doi. 10.1002/cncr.33403
- By:
- Publication type:
- Article